3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
7
Active not recruiting
7
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Dermatologic
3
CNS
3
Thoracic
2
Plasma cell
2
Head & Neck
2
Gastrointestinal
2
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Endocrine
1
Classical hematology
1
Breast
1
Conditions
Osteosarcoma
1
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
cabozantinib
×
Sarcoma
×
Clear all
NCT06341712
2026-03-31
CabOSTar
Ipsen
Phase 2
Terminated
10 enrolled